Cellectis (NASDAQ: CLLS)
Cellectis Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Cellectis Company Info
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
News & Analysis
Why Cellectis' Shares Rose 22.7% This Week
The company bucked the recent downward trend for biotech companies.
Why Cellectis Stock Rose 20.7% This Week
Investors saw a bargain when the stock hit its 52-week low early in the week.
These Gene-Editing Pioneers Are Making Bold Bets in Agriculture
Investors shouldn't forget that the world of biotech extends beyond biopharmaceuticals.
Did Cellectis Just Provide a Glimpse of the Future of Cellular Medicine?
The gene editing company published a proof-of-concept for "smart" immunotherapies. The idea may catch on.
5 Top Gene-Editing Stocks for 2019
The future of treating disease might be gene editing, and these five stocks have the most promising technologies.
Is Cellectis SA Stock a Buy Now?
Despite getting passed along to a biotech start-up, Cellectis could have a bright future.
Can Been-There Biotech Entrepreneur Arie Belldegrun Do It Yet Again?
Belldegrun's Allogene Therapeutics has just inked a transformative deal to land Pfizer's CAR-T cancer gene therapy program.
Why Micron Technology, Mechel, and Cellectis Slumped Today
Find out why these stocks missed out on the rally.
Valuation
Earnings Transcripts
Cellectis SA (CLLS) Q3 2021 Earnings Call Transcript
CLLS earnings call for the period ending September 30, 2021.
Cellectis SA (CLLS) Q2 2021 Earnings Call Transcript
CLLS earnings call for the period ending August 6, 2021.
Cellectis SA (CLLS) Q4 2020 Earnings Call Transcript
CLLS earnings call for the period ending December 31, 2020.
Cellectis SA (CLLS) Q3 2020 Earnings Call Transcript
CLLS earnings call for the period ending September 30, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.